

Bone Therapeutics announces results of Annual General Meeting

Company reshapes and strengthens its Board of Directors with focus on improving governance and diversity

Additional Extraordinary Shareholders Meeting to be conducted in July

Gosselies, Belgium, 14 June 2018, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces the results of its Annual General Meeting (AGM) held at the Company's headquarters in Gosselies.

At the AGM, held on 13 June 2018, the appointment of Jean Stéphenne as Chairman of the Company's Board of Directors and the appointments of Claudia D'Augusta, Dirk Dembski (representative of Marc Alexander Initiative & Advisory GmbH) and Jean-Paul Prieels as Independent Directors were approved. In addition, Jean-Luc Vandebroek, Chief Financial Officer, was nominated to the Board as an Executive Director.

After a successful tenure during which they have helped transform a promising spin-off into a mature listed biotech company with a clinically advanced pipeline, Chris Buyse, Paul Magrez and Thierry François have announced their resignation from the Board. To maintain an agile structure, the Board of Directors has decided to limit the number of Directors to nine.

The changes in board composition are part of an ongoing reshaping exercise, which aims to further enhance the Board's effectiveness with an increased attention to diversity in both gender and expertise. The new board composition will allow the Company to be optimally prepared for future challenges.

Jean Stéphenne, Chairman of the Board of Directors of Bone Therapeutics, commented: *"I would like to personally thank Chris, Paul and Thierry for their invaluable guidance to Bone Therapeutics over the past eight years during which time the Company has, with their support and strategic counsel, developed into a successful public company."*

"I would also like to take this opportunity to welcome our new board members. We expect their strong experience and expertise to significantly benefit the Company as we continue the development of our proprietary bone cell therapy programs. As Bone Therapeutics advances its products towards commercialisation, we will continue to focus on the strength and diversity of the Board and will seek to recruit individuals who can provide the highest quality of governance and stewardship going forward."

As the shareholders present at the subsequent Extraordinary Shareholders Meeting did not represent the required quorum of 50% of the share capital, an additional Extraordinary General Shareholders meeting will be

conducted on Monday 9 July 2018.